Novonesis Raises 2026 Sales Growth Forecast to 7-8% — Novonesis A/S

Event summary

Novonesis (Novozymes A/S) increased its full-year 2026 organic sales growth outlook from 5-7% to 7-8%.
The adjusted EBITDA margin is now expected to be at the higher end of the 37-38% range.
The updated outlook is based on stronger-than-expected performance in H1 2026 and optimistic projections for the rest of the year.
The H1 2026 announcement is scheduled for August 19, 2026.

The big picture

Novonesis's upgraded outlook reflects stronger-than-expected performance in the first half of 2026, signaling robust demand in the biotechnology sector. The company's ability to maintain this momentum will be critical in a competitive market where profitability and growth are key differentiators. Investors will be watching closely to see if this performance is sustainable and whether it translates into long-term strategic advantages.

What we're watching

Revenue Momentum: How sustained demand will affect full-year revenue growth...
Profitability Trends: Whether the higher EBITDA margin can be maintained through 2026...
Market Positioning: The pace at which Novonesis can capitalize on its improved outlook to gain market share...